Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab

被引：6

作者：

Aya, Francisco ^{[1
,2
]}

Fernandez-Martinez, Aranzazu ^{[1
,2
]}

Gaba, Lydia ^{[1
,2
]}

Victoria, Ivan ^{[1
,2
]}

Tosca, Monica ^{[1
,2
]}

Carrera, Cristina ^{[3
,4
,5
]}

Prat, Aleix ^{[1
,2
]}

Arance, Ana ^{[1
,2
]}

机构：

[1] Hosp Clin Barcelona, Med Oncol Dept, Barcelona, Spain

[2] Inst Invest Biomed August Pi & Sunyer IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain

[3] Hosp Clin Barcelona, Dept Dermatol, Barcelona, Spain

[4] Inst Salud Carlos III, CIBER Enfermedades Raras, Madrid, Spain

[5] Univ Barcelona, Barcelona, Spain

来源：

IMMUNOTHERAPY | 2016年 / 8卷 / 06期

关键词：

anti-CTLA-4; anti-PD-1; immune-related adverse event; melanoma; TOXICITIES; ANTI-PD-1; SAFETY; CHEMOTHERAPY; DACARBAZINE; NIVOLUMAB; SURVIVAL;

D O I：

10.2217/imt-2015-0025

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Currently, limited data exist on the safety of pembrolizumab in patients with metastatic melanoma who have developed severe immune-related adverse events following treatment with ipilimumab. We report a 45-year-old male patient with BRAF-mutant metastatic melanoma who discontinued treatment with ipilimumab due to treatment-related grade 3 colitis and was subsequently treated with the anti-programmed cell death 1 protein (PD-1) antibody pembrolizumab. He has been on treatment with pembrolizumab for more than 20 months with no major toxicities and has achieved an objective partial response, which is ongoing.

引用

页码：687 / 692

页数：6

共 21 条

[1] Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma:: A phase III study [J].

Avril, MF ;

Aamdal, S ;

Grob, JJ ;

Hauschild, A ;

Mohr, P ;

Bonerandi, JJ ;

Weichenthal, M ;

Neuber, K ;

Bieber, T ;

Gilde, K ;

Porta, VG ;

Fra, J ;

Bonneterre, J ;

Saïag, P ;

Kamanabrou, D ;

Pehamberger, H ;

Sufliarsky, J ;

Larriba, JLG ;

Scherrer, A ;

Menu, Y .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1118-1125

[2] Final Version of 2009 AJCC Melanoma Staging and Classification [J].

Balch, Charles M. ;

Gershenwald, Jeffrey E. ;

Soong, Seng-jaw ;

Thompson, John F. ;

Atkins, Michael B. ;

Byrd, David R. ;

Buzaid, Antonio C. ;

Cochran, Alistair J. ;

Coit, Daniel G. ;

Ding, Shouluan ;

Eggermont, Alexander M. ;

Flaherty, Keith T. ;

Gimotty, Phyllis A. ;

Kirkwood, John M. ;

McMasters, Kelly M. ;

Mihm, Martin C., Jr. ;

Morton, Donald L. ;

Ross, Merrick I. ;

Sober, Arthur J. ;

Sondak, Vernon K. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6199-6206

[3]

Dummer R, 2014, MEL BRIDG M 2014 NAP

[4] Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects [J].

Garbe, Claus ;

Eigentler, Thomas K. ;

Keilholz, Ulrich ;

Hauschild, Axel ;

Kirkwood, John M. .

ONCOLOGIST, 2011, 16 (01) :5-24

[5] Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma [J].

Hamid, Omid ;

Robert, Caroline ;

Daud, Adil ;

Hodi, F. Stephen ;

Hwu, Wen-Jen ;

Kefford, Richard ;

Wolchok, Jedd D. ;

Hersey, Peter ;

Joseph, Richard W. ;

Weber, Jeffrey S. ;

Dronca, Roxana ;

Gangadhar, Tara C. ;

Patnaik, Amita ;

Zarour, Hassane ;

Joshua, Anthony M. ;

Gergich, Kevin ;

Elassaiss-Schaap, Jeroen ;

Algazi, Alain ;

Mateus, Christine ;

Boasberg, Peter ;

Tumeh, Paul C. ;

Chmielowski, Bartosz ;

Ebbinghaus, Scot W. ;

Li, Xiaoyun Nicole ;

Kang, S. Peter ;

Ribas, Antoni .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (02) :134-144

[6] Emerging Immunotherapies in the Treatment of Non-small Cell Lung Cancer (NSCLC) The Role of Immune Checkpoint Inhibitors [J].

Langer, Corey J. .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (04) :422-430

[7] Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies [J].

Naidoo, J. ;

Page, D. B. ;

Li, B. T. ;

Connell, L. C. ;

Schindler, K. ;

Lacouture, M. E. ;

Postow, M. A. ;

Wolchok, J. D. .

ANNALS OF ONCOLOGY, 2015, 26 (12) :2375-2391

[8] Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial [J].

Ribas, Antoni ;

Puzanov, Igor ;

Dummer, Reinhard ;

Schadendorf, Dirk ;

Hamid, Omid ;

Robert, Caroline ;

Hodi, F. Stephen ;

Schachter, Jacob ;

Pavlick, Anna C. ;

Lewis, Karl D. ;

Cranmer, Lee D. ;

Blank, Christian U. ;

O'Day, Steven J. ;

Ascierto, Paolo A. ;

Salama, April K. S. ;

Margolin, Kim A. ;

Loquai, Carmen ;

Eigentler, Thomas K. ;

Gangadhar, Tara C. ;

Carlino, Matteo S. ;

Agarwala, Sanjiv S. ;

Moschos, Stergios J. ;

Sosman, Jeffrey A. ;

Goldinger, Simone M. ;

Shapira-Frommer, Ronnie ;

Gonzalez, Rene ;

Kirkwood, John M. ;

Wolchok, Jedd D. ;

Eggermont, Alexander ;

Li, Xiaoyun Nicole ;

Zhou, Wei ;

Zernhelt, Adriane M. ;

Lis, Joy ;

Ebbinghaus, Scot ;

Kang, S. Peter ;

Daud, Adil .

LANCET ONCOLOGY, 2015, 16 (08) :908-918

[9] Pembrolizumab versus Ipilimumab in Advanced Melanoma [J].

Robert, Caroline ;

Schachter, Jacob ;

Long, Georgina V. ;

Arance, Ana ;

Grob, Jean Jacques ;

Mortier, Laurent ;

Daud, Adil ;

Carlino, Matteo S. ;

McNeil, Catriona ;

Lotem, Michal ;

Larkin, James ;

Lorigan, Paul ;

Neyns, Bart ;

Blank, Christian U. ;

Hamid, Omid ;

Mateus, Christine ;

Shapira-Frommer, Ronnie ;

Kosh, Michele ;

Zhou, Honghong ;

Ibrahim, Nageatte ;

Ebbinghaus, Scot ;

Ribas, Antoni .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (26) :2521-2532

[10] Nivolumab in Previously Untreated Melanoma without BRAF Mutation [J].

Robert, Caroline ;

Long, Georgina V. ;

Brady, Benjamin ;

Dutriaux, Caroline ;

Maio, Michele ;

Mortier, Laurent ;

Hassel, Jessica C. ;

Rutkowski, Piotr ;

McNeil, Catriona ;

Kalinka-Warzocha, Ewa ;

Savage, Kerry J. ;

Hernberg, Micaela M. ;

Lebbe, Celeste ;

Charles, Julie ;

Mihalcioiu, Catalin ;

Chiarion-Sileni, Vanna ;

Mauch, Cornelia ;

Cognetti, Francesco ;

Arance, Ana ;

Schmidt, Henrik ;

Schadendorf, Dirk ;

Gogas, Helen ;

Lundgren-Eriksson, Lotta ;

Horak, Christine ;

Sharkey, Brian ;

Waxman, Ian M. ;

Atkinson, Victoria ;

Ascierto, Paolo A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :320-330

← 1 2 3 →